FLT3-TKD突变的临床试验
总计1917个结果
-
University of Maryland, BaltimoreNeuroscience Research Australia完全的
-
Astellas Pharma Global Development, Inc.批准上市急性髓系白血病 (AML) | FMS 样酪氨酸激酶 3 (FLT3) 突变美国, 加拿大, 日本
-
Astellas Pharma Global Development, Inc.招聘中
-
Senti Biosciences招聘中反洗钱/材料数据表 | CD33 表达血液恶性肿瘤 | FLT3 表达血液恶性肿瘤美国, 澳大利亚
-
xunaNanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... 和其他合作者撤销
-
China Medical University Hospital尚未招聘非小细胞肺癌 | 表皮生长因子受体基因突变 | EGFR-TKI 耐药突变
-
Tianjin Medical University Cancer Institute and...招聘中非小细胞肺癌 | EGFR激活突变 | EGFR-TKI 耐药突变 | 细胞周期失调中国
-
Second Xiangya Hospital of Central South UniversityThe First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central South University 和其他合作者招聘中肺癌,非小细胞 | 循环肿瘤DNA | 表皮生长因子受体基因突变 | EGFR-TKI 耐药突变 | 初级阻力中国
-
Degan LuWu Jieping Medical Foundation尚未招聘肺癌 | 安罗替尼 | TKI耐药 | EGFR敏感突变 | 平珠单抗
-
University of CopenhagenNovo Nordisk A/S; Steno Diabetes Center Copenhagen完全的
-
University of FloridaJuvenile Diabetes Research Foundation招聘中
-
Shenzhen People's Hospital未知
-
McGill University Health Centre/Research Institute...Heart and Stroke Foundation of Canada招聘中
-
Fan Fan Hou未知
-
Astellas Pharma Inc终止未接受过 EGFR-TKI 治疗且携带 EGFR 激活突变的 NSCLC 患者日本
-
UConn HealthNational Institute of Dental and Craniofacial Research (NIDCR)完全的
-
Northwestern UniversityNational Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer Center主动,不招人复发性成人急性髓性白血病 | 难治性急性髓性白血病 | 具有 t(9;11)(p22.3;q23.3) 的急性髓系白血病; MLLT3-KMT2A | 成纤维细胞生长因子基本形式测量 | FLT3 内部串联复制美国
-
FibroGenAstraZeneca; Astellas Pharma Europe B.V.完全的
-
Nantes University HospitalUniversity Hospital, Angers招聘中
-
Wuhan Union Hospital, China招聘中
-
Shanghai Hengrui Pharmaceutical Co., Ltd.招聘中
-
Pamela MunsterNational Cancer Institute (NCI)招聘中BRCA1突变 | BRCA2突变 | PALB2基因突变 | ATM基因突变 | BRCA突变 | 检查点激酶 2 基因突变美国
-
University of California, San FranciscoGlaxoSmithKline招聘中